Variable; number (%) unless indicated otherwise | CHILDREN N = 64 | ADULTS N = 175 | TOTAL N = 239 | |||
---|---|---|---|---|---|---|
Variable; number (%) unless indicated otherwise | INPATIENTS | OUTPATIENTS | INPATIENTS | OUTPATIENTS | INPATIENTS | OUTPATIENTS |
N = 48 | N = 16 | N = 107 | N = 68 | N = 155 | N = 84 | |
< 2 years | 11 (23) | 2 (12.5) | ||||
2–5 years | 13 (27.1) | 7 (43.75) | ||||
5–18 years | 24 (50) | 7 (43.75) | ||||
Age (years) median (IQR) | 4.9 (2.7–7.4) | 47 (.3.7–8.8) | 60.5 (48–70.6) | 50.8 (37.3–59.4) | ||
Male | 26 (54.2) | 9 (56.3) | 53 (49.5) | 34 (20) | 79 (51) | 43 (51,2) |
HSCT | 2 (4.2) | 6 (37.5) | 24 (22.4) | 35 (51.5) | 26 (16.8) | 41 (48.8) |
Autologous | 0 | 0 | 9 (8.4) | 1 (1.5) | 9 (5.8) | 1(1.2) |
Allogeneic | 0 | 8(100) | 15 (14) | 34 (50) | 12(7,7) | 45(53,6) |
Matched | 0 | 3 (18.8) | 5 (4.7) | 19(28) | 5(3,2) | 22(26,2) |
Mismatched | 0 | 0 | 1 (1) | 0 | 1(0,6) | 0 |
Unrelated | 2 (4.2) | 1 (6.3) | 9 (8.4) | 15(22,1) | 11(7,1) | 16(19) |
SOT | 3(6.3) | 2 (12.5) | 32 (30) | 26(38,2) | 35(22,6) | 28(33,3) |
Leukaemia /lymphoma | 23 (47.9) | 6 (37.5) | 18 (16.8) | 3(4,4) | 41(26,5) | 9(10,7) |
Solid tumor | 9 (18.8) | 2 (12.5) | 15 (14) | 1(1,5) | 24(15,5) | 3(3,6) |
Chronic immuno-suppression | 6 (12.5) | 0 | 18 (16.8) | 2 (3.0) | 24(15,5) | 2(2,4) |
PID | 5 (10.4) | 0 | 0 | 1(1) | 5(3,2) | 1(1,2) |
GVHD among allogeneic HSCT recipients | 1 (2.1) | 4 (25) | 9 (8.4) | 21 (30.9) | 10(6,5) | 25(29,8) |
Bacterial co-infection | 8 (16.7) | 1(6.3) | 25 (23.4) | 2 (3) | 33(21,3) | 3(3,6) |
Viral co-infection | 12 (25) | 6 (37.5) | 22 (20.6) | 12 (17.7) | 34(21,9) | 18(21,4) |
ANC, median, (IQR) | 1.1 (0.5–3.1) | 1.7 (1.6–4.2) | 4.6 (1.4–8.1) | 3.5 (2.6–5.3) | 3.4 (0.9–6.7) | 3.3 (2.3–5.3) |
ALC, median (IQR) | 0.8 (0.2–2.1) | 1.6 (0.7–1.9) | 0.7 (0.1–1.1) | 1.1 (0.6–1.9) | 0,7(0,2–1,4) | 1.1 (0.6–1.9) |
Oral ribavirin treatment | 1 (2.1) | 1 (6.3) | 24 (22.4) | 12 (17,6) | 25 (16.1) | 13(15,5) |
Palivizumab treatment | 2 (4.2) | 0 | 7 (6.5) | 1 (1.5) | 9 (5,8) | 1(1,2) |